标题
Pacritinib to treat myelofibrosis patients with thrombocytopenia
作者
关键词
-
出版物
Expert Review of Hematology
Volume -, Issue -, Pages 1-8
出版商
Informa UK Limited
发表日期
2018-07-13
DOI
10.1080/17474086.2018.1500456
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Outcomes of patients with myelofibrosis treated with compassionate use pacritinib: a sponsor-independent international study
- (2018) J. Mascarenhas et al. ANNALS OF HEMATOLOGY
- Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis
- (2018) John Mascarenhas et al. JAMA Oncology
- A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis
- (2017) F Passamonti et al. LEUKEMIA
- Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial
- (2017) Ruben A Mesa et al. Lancet Haematology
- Phase II study of SB1518, an orally available novel JAK2 inhibitor, in patients with myelofibrosis.
- (2017) H. J. Deeg et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies
- (2016) Srdan Verstovsek et al. Journal of Hematology & Oncology
- Should we be treating lower risk myelofibrosis patients with a JAK2 inhibitor?
- (2016) Guido Lancman et al. Expert Review of Hematology
- Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis
- (2015) R. S. Komrokji et al. BLOOD
- Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis
- (2014) R. Rampal et al. BLOOD
- A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis
- (2013) J. Mascarenhas et al. BLOOD
- Targeting IRAK1 as a Therapeutic Approach for Myelodysplastic Syndrome
- (2013) Garrett W. Rhyasen et al. CANCER CELL
- Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
- (2013) Thorsten Klampfl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapies
- (2012) B Luo et al. ONCOGENE
- Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma
- (2011) Anthony D. William et al. JOURNAL OF MEDICINAL CHEMISTRY
- SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies
- (2011) S Hart et al. LEUKEMIA
- DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
- (2010) Naseema Gangat et al. JOURNAL OF CLINICAL ONCOLOGY
- Risk factors for leukemic transformation in patients with primary myelofibrosis
- (2008) Jocelin Huang et al. CANCER
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started